HUMAN IL-10 RECEPTOR ALPHA FUSION PROTEINS
Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., an IL-10 trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion protein, or an expression vector encoding for the fusion proteins, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Europäisches Patentamt - (2024) vom: 15. Feb. Zur Gesamtaufnahme - year:2024 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
LARSON CHRISTOPHER [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-02-15, Last update posted on www.tib.eu: 2024-03-20, Last updated: 2024-03-29 |
---|
Patentnummer: |
US2024052016 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA000808407 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA000808407 | ||
003 | DE-627 | ||
005 | 20240329155005.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240315s2024 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA000808407 | ||
035 | |a (EPA)US2024052016 | ||
035 | |a (EPA)65902489 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a LARSON CHRISTOPHER |e verfasserin |4 aut | |
245 | 1 | 0 | |a HUMAN IL-10 RECEPTOR ALPHA FUSION PROTEINS |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2024-02-15, Last update posted on www.tib.eu: 2024-03-20, Last updated: 2024-03-29 | ||
520 | |a Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., an IL-10 trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion protein, or an expression vector encoding for the fusion proteins, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders. | ||
650 | 4 | |a bio | |
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
650 | 4 | |a che | |
650 | 4 | |a 615 | |
700 | 0 | |a REID TONY R |4 aut | |
700 | 0 | |a ORONSKY BRYN T |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 15. Feb. |
773 | 1 | 8 | |g year:2024 |g day:15 |g month:02 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/65902489/publication/US2024052016A1?q=US2024052016 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
951 | |a AR | ||
952 | |j 2024 |b 15 |c 02 |